



DRUG QUANTITY MANAGEMENT POLICY – PER RX

- POLICY:** Antidepressants – Serotonin and Norepinephrine Reuptake Inhibitors Drug Quantity Management Policy – Per Rx
- Cymbalta® (duloxetine delayed-release capsules – Lilly, generic)
 - Desvenlafaxine extended-release tablets (Sun/Ranbaxy [brand product])
 - Drizalma Sprinkle™ (duloxetine delayed-release capsules – Sun)
 - Duloxetine 40 mg delayed-release capsules (generic only)
 - Effexor® XR (venlafaxine extended-release capsules – Viatrix/Pfizer, generic)
 - Fetzima® (levomilnacipran extended-release capsules – AbbVie)
 - Pristiq® (desvenlafaxine succinate extended-release tablets – Wyeth/Pfizer, generic)
 - Savella® (milnacipran tablets – AbbVie)
 - Venlafaxine besylate extended-release tablets (Almatica [brand product])
 - Venlafaxine hydrochloride tablets (generic only)
 - Venlafaxine hydrochloride extended-release tablets (generic only)

REVIEW DATE: 07/01/2024

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

All of the serotonin and norepinephrine reuptake inhibitors (SNRIs), with the exception of Savella, are indicated for the treatment of Major Depressive Disorder (MDD).¹⁻¹⁰ Some of the SNRIs carry additional indications (Table 1).

Table 1. FDA-Approved Indications in Adults.¹⁻¹⁰

Brand (generic)	MDD	GAD	Social Anxiety Disorder	Panic Disorder	DPN Pain	Chronic Musculoskeletal Pain	Fibromyalgia
Cymbalta® (duloxetine delayed-release capsules, generic)	X	X^			X	X	X#
duloxetine 40 mg delayed-release capsules (generic to discontinued Irenka™)	X	X^			X	X	
Drizalma Sprinkle™ (duloxetine delayed-release capsules)	X	X^			X	X	X
Desvenlafaxine extended-release tablets (brand product)	X						
Pristiq® (desvenlafaxine succinate extended-release tablets, generic)	X						
venlafaxine HCl immediate-release tablets (generic to discontinued Effexor®)	X						
venlafaxine besylate extended-release tablets (brand product)	X	X					
Effexor XR® (venlafaxine HCl extended-release capsules, generic)	X	X	X	X			
Venlafaxine HCl extended-release tablets (generic only)	X		X				

Table 1. FDA-Approved Indications in Adults.¹⁻¹⁰

Brand (generic)	MDD	GAD	Social Anxiety Disorder	Panic Disorder	DPN Pain	Chronic Musculoskeletal Pain	Fibromyalgia
Fetzima® (levomilnacipran extended-release capsules)	X						
Savella®							X

(milnacipran tablets)							
-----------------------	--	--	--	--	--	--	--

MDD – Major Depressive Disorder; GAD – Generalized Anxiety Disorder; DPN – Diabetic Peripheral Neuropathy; ^ Approved for use in patients \geq 7 years of age with GAD; # Approved for use in patients \geq 13 years of age with fibromyalgia.

Dosing and Availability

Dosing and availability for the SNRIs is in the Drug Quantity Limits table below.

POLICY STATEMENT

This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of the serotonin and norepinephrine reuptake inhibitors. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 1 year in duration unless otherwise noted below.

Drug Quantity Limits

Brand (generic)	FDA-Approved Dosing	Availability	Retail Maximum Quantity per Rx ^a	Home Delivery Maximum Quantity per Rx ^a
Cymbalta® (duloxetine delayed-release capsules, generic)	<ul style="list-style-type: none"> • <u>MDD</u>: 20 mg BID to 60 mg/day (given either BID or QD). May start with 30 mg QD x 1 week before increasing to 60 mg/day. • <u>Fibromyalgia and chronic musculoskeletal pain</u>: 60 mg/day. • <u>GAD and DPNP pain</u>: 60 mg QD. May use 30 mg QD for elderly or pediatric patients. • Maximum doses range from 60 mg to 120 mg/day. 	20 mg capsules	60 capsules	180 capsules
		30 mg capsules	30 capsules	90 capsules
		60 mg capsules	60 capsules	180 capsules
duloxetine delayed-release capsules (generic to discontinued Irenka™)	<ul style="list-style-type: none"> • <u>MDD</u>: 20 mg BID to 60 mg/day (given either BID or QD). May start with 30 mg QD x 1 week before increasing to 60 mg/day. • <u>Chronic musculoskeletal pain</u>: 60 mg/day. Begin with 30 mg/day for 1 week prior to increasing to 60 mg/day. • <u>GAD and DPNP pain</u>: 60 mg QD. May use 30 mg QD for elderly or pediatric patients. • Maximum doses range from 60 mg to 120 mg/day. 	40 mg capsules	30 capsules	90 capsules

Drug Quantity Limits (continued)

Brand (generic)	FDA-Approved Dosing	Availability	Retail Maximum Quantity per Rx ^a	Home Delivery Maximum Quantity per Rx ^a
Drizalma Sprinkle™ (duloxetine delayed-release capsules)	<ul style="list-style-type: none"> • <u>MDD</u>: 20 mg BID to 60 mg/day (given either BID or QD). May start with 30 mg QD x 1 week before increasing to 60 mg/day. • <u>Fibromyalgia and chronic musculoskeletal pain</u>: 60 mg/day. • <u>GAD and DPNP pain</u>: 60 mg QD. May use 30 mg QD for elderly or pediatric patients. • Maximum doses range from 60 mg to 120 mg/day. 	20 mg capsules	60 capsules	180 capsules
		30 mg capsules	30 capsules	90 capsules
		40 mg capsules	30 capsules	90 capsules
		60 mg capsules	60 capsules	180 capsules
Desvenlafaxine extended-release tablets (brand product)	<ul style="list-style-type: none"> • <u>MDD</u>: 50 mg QD (starting dose and therapeutic dose). Doses of 10 mg to 400 mg/day have been studied and were shown to be effective. However, no additional benefit was demonstrated at doses > 50 mg/day and AEs and discontinuations were more frequent at higher doses. • Maximum dose in severe renal impairment or ESRD is 25 mg QD or 50 mg every other day. 	50 mg tablets	30 tablets	90 tablets
		100 mg tablets	30 tablets	90 tablets
Pristiq® (desvenlafaxine succinate extended-release tablets, generic)	<ul style="list-style-type: none"> • <u>MDD</u>: 50 mg QD (starting dose and therapeutic dose). Doses of 10 mg to 400 mg/day have been studied and were shown to be effective. However, no additional benefit was demonstrated at doses > 50 mg/day and AEs and discontinuations were more frequent at higher doses. Maximum dose in severe renal impairment or ESRD is 25 mg QD or 50 mg every other day. 	25 mg tablets	30 tablets	90 tablets
		50 mg tablets	30 tablets	90 tablets
		100 mg tablets	30 tablets	90 tablets
venlafaxine HCl immediate-release tablets (generic to discontinued Effexor®)	<ul style="list-style-type: none"> • <u>MDD</u>: 75 mg/day (administered in 2 to 3 divided doses). May be increased (in 75 mg/day increments) to 150 mg/day and further increased to 225 mg/day based on tolerability and desired effect. Doses of up to 350 mg to 375 mg/day (in three divided doses) have been studied in severely depressed patients. 	25 mg tablets	90 tablets	270 tablets
		37.5 mg tablets	90 tablets	270 tablets
		50 mg tablets	90 tablets	270 tablets
		75 mg tablets	90 tablets	270 tablets
		100 mg tablets	90 tablets	270 tablets

	Reduce the total daily dose by 25% in patients with renal impairment. Reduce the dose by 50% in patients with mild to moderate hepatic impairment or those undergoing hemodialysis.			
--	---	--	--	--

Drug Quantity Limits (continued)

Brand (generic)	FDA-Approved Dosing	Availability	Retail Maximum Quantity per Rx^a	Home Delivery Maximum Quantity per Rx^a
Effexor XR® (venlafaxine HCl extended-release capsules, generic)	<ul style="list-style-type: none"> • <u>MDD and GAD</u>: 75 mg/day. Some patients may start at 37.5 mg/day for 4 to 7 days before increasing to 75 mg/day. If not responding to 75 mg/day, may increase dose up to a maximum of 225 mg/day in increments of 75 mg/day as needed. • <u>Social Anxiety Disorder</u>: 75 mg/day. • <u>Panic disorder</u>: 37 mg/day x 7 days, then 75 mg/day up to a maximum of 225 mg/day (increased in 75 mg/day increments as needed). • Reduce dose by 25% to 50% for patients with mild or moderate renal impairment and by 50% in patients with severe hepatic impairment, hepatic cirrhosis, or those with severe renal impairment/undergoing hemodialysis. 	37.5 mg capsules	30 capsules	90 capsules
		75 mg capsules	90 capsules	270 capsules
		150 mg capsules	30 capsules	90 capsules
Venlafaxine HCl extended-release tablets (generic only)	<ul style="list-style-type: none"> • <u>MDD</u>: 75 mg QD. Some patients may start at 37.5 mg QD for 4-7 days before increasing. If no response to the initial dose, may increase up to 225 mg QD in increments of 75 mg/day). 350 mg/day (range 150 mg to 275 mg/day) has been studied in more severely depressed patients. • <u>Social Anxiety Disorder</u>: 75 mg QD. • Reduce dose by 25% to 50% for patients with mild or moderate renal impairment and by 50% in patients with severe hepatic impairment, hepatic cirrhosis, or those with severe renal 	37.5 mg tablets	30 tablets	90 tablets
		75 mg tablets	30 tablets	90 tablets
		150 mg tablets	30 tablets	90 tablets
		225 mg tablets	30 tablets	90 tablets

	impairment/undergoing hemodialysis.			
Venlafaxine besylate extended-release tablets (brand product)	<p>This product is only available as a 112.5 mg tablet, therefore, use another venlafaxine extended-release product for dose initiation, titration, and administration of doses less than 112.5 mg QD. Tablets should be swallowed whole; do not divide, crush, chew, or place in water prior to administration.</p> <ul style="list-style-type: none"> • <u>MDD and GAD</u>: 112.5 mg QD in patients who have received at least 75 mg per day of another venlafaxine extended-release product for at least 4 days. If the patient is not responding to their current venlafaxine dose, they may benefit from a dose increase to a maximum of 225 mg per day. The dose should be increased in increments of up to 75 mg per day, as needed, using another venlafaxine extended-release product, at intervals of 4 days or more. 	112.5 mg tablets	30 tablets	90 tablets

Drug Quantity Limits (continued)

Brand (generic)	FDA-Approved Dosing	Availability	Retail Maximum Quantity per Rx^a	Home Delivery Maximum Quantity per Rx^a
Fetzima® (levomilnacipran extended-release capsules)	<ul style="list-style-type: none"> • <u>MDD</u>: 40 mg to 120 mg QD (starting at 20 mg QD, increased to 40 mg QD, then increased in 40 mg/day intervals). <p>Maximum dose in moderate renal impairment is 80 mg QD and in severe renal impairment the dose should not exceed 40 mg QD.</p>	20 mg capsules	30 capsules	90 capsules
		40 mg capsules	30 capsules	90 capsules
		80 mg capsules	30 capsules	90 capsules
		120 mg capsules	30 capsules	90 capsules
		Titration Pack (2 x 20 mg capsules and 26 x 40 mg capsules)	1 pack (28 capsules)	
Savella® (milnacipran tablets)	<p>Titrate Savella according to the following schedule (based on efficacy and tolerability):</p> <ul style="list-style-type: none"> • Day 1: 12.5 mg once • Days 2-3: 12.5 mg BID • Days 4-7: 25 mg BID 	12.5 mg tablets	60 tablets	180 tablets
		25 mg tablets	60 tablets	180 tablets
		50 mg tablets	60 tablets	180 tablets

	<ul style="list-style-type: none"> • After Day 7: 50 mg BID • May increase to 100 mg BID based on individual patient response. • In patients with severe renal impairment, the maintenance dose should be reduced by 50% to 25 mg BID and may be increased to 50 mg BID based on individual response. 	100 mg tablets	60 tablets	180 tablets
		Titration Pack (5 x 12.5-mg tablets, 8 x 25-mg tablets, and 42 x 50 mg tablets)	1 pack (55 tablets)	

^a When possible, the patient should be referred to higher strength capsule/tablet if a higher dose is needed. MDD – Major depressive disorder; BID – Twice daily; QD – Once daily; GAD – Generalized Anxiety Disorder; DPNP – Diabetic peripheral neuropathy pain; ESRD – End-stage renal disease.

Antidepressants – Serotonin and Norepinephrine Reuptake Inhibitors Drug Quantity Management Policy – Per Rx product(s) is(are) covered as medically necessary when the following criteria is(are) met. Any other exception is considered not medically necessary.

CRITERIA

Duloxetine 20 mg delayed-release capsules (Cymbalta, generic), Drizalma Sprinkle 20 mg delayed-release capsules

1. If the patient is taking 40 mg twice daily, approve 120 capsules per dispensing at retail and 360 capsules per dispensing at home delivery.
2. If the patient is taking 20 mg three times daily or is taking a 40 mg dose and a 20 mg dose per day, approve 90 capsules per dispensing at retail and 270 capsules per dispensing at home delivery.
3. If the patient is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets be used AND would otherwise require two or more strengths be used), approve the requested quantity, not to exceed 180 capsules per dispensing at retail or 540 capsules per dispensing at home delivery.

Note: This override provides for a dose up to 120 mg per day.

Duloxetine 30 mg delayed-release capsules (Cymbalta, generic), Drizalma Sprinkle 30 mg delayed-release capsules

1. If the patient is taking 30 mg twice daily, approve 60 capsules per dispensing at retail and 180 capsules per dispensing at home delivery.
2. If the patient is taking 30 mg three times daily or is taking a 60 mg dose and a 30 mg dose per day, approve 90 capsules per dispensing at retail and 270 capsules per dispensing at home delivery.
3. If the patient is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets be used AND would otherwise require two or more strengths be used), approve the requested quantity, not to exceed 120 capsules per dispensing at retail or 360 capsules per dispensing at home delivery.

Note: This override provides for a dose up to 120 mg per day.

Duloxetine 40 mg delayed-release capsules (generic to discontinued Irenka),
Drizalma Sprinkle 40 mg delayed-release capsules

1. If the patient is taking a dose of 80 mg per day, approve 60 capsules per dispensing at retail and 180 capsules per dispensing at home delivery.

Duloxetine 60 mg delayed-release capsules (Cymbalta, generic), Drizalma Sprinkle
60 mg delayed-release capsules

No overrides recommended.

Desvenlafaxine 25 mg extended-release tablets (Pristiq, generic)

1. If the patient requires the dose to be divided twice daily, approve the requested quantity, not to exceed 480 tablets per dispensing at retail or 1,440 tablets per dispensing at home delivery.

Note: This override provides for a dose up to 400 mg per day.

2. If the patient is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets be used AND would otherwise require two or more strengths be used), approve the requested quantity, not to exceed 480 tablets per dispensing at retail or 1,440 tablets per dispensing at home delivery.

Note: This override provides for a dose up to 400 mg per day.

Desvenlafaxine 50 mg extended-release tablets and desvenlafaxine 50 mg
extended-release tablets (Pristiq, generic)

1. If the patient requires the dose to be divided twice daily, approve the requested quantity, not to exceed 240 tablets per dispensing at retail or 720 tablets per dispensing at home delivery.

Note: This override provides for a dose up to 400 mg per day.

2. If the patient is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets be used AND would otherwise require two or more strengths be used), approve the requested quantity, not to exceed 240 tablets per dispensing at retail or 720 tablets per dispensing at home delivery.

Note: This override provides for a dose up to 400 mg per day.

Desvenlafaxine 100 mg extended-release tablets and desvenlafaxine 100 mg
extended-release tablets (Pristiq, generic)

1. If the patient has been started and stabilized on a dose greater than 100 mg per day or if the patient has been receiving 100 mg daily and the dose is now being increased, approve the requested quantity, not to exceed 120 tablets per dispensing at retail or 360 tablets per dispensing at home delivery.

Note: This override provides for a dose up to 400 mg per day.

Venlafaxine HCl 25 mg immediate-release tablets

1. If the patient is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets be used AND would otherwise require two or more strengths be used), approve the requested quantity, not to exceed 450 tablets per dispensing at retail or 1,350 tablets per dispensing at home delivery.

Note: This override provides for a dose up to 375 mg per day.

Venlafaxine HCl 37.5 mg immediate-release tablets

1. If the patient is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets be used AND would otherwise require two or more strengths be used), approve the requested quantity, not to exceed 300 tablets per dispensing at retail or 900 tablets per dispensing at home delivery.

Note: This override provides for a dose up to 375 mg per day.

Venlafaxine HCl 50 mg immediate-release tablets

1. If the patient is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets be used AND would otherwise require two or more strengths be used), approve the requested quantity, not to exceed 210 tablets per dispensing at retail or 630 tablets per dispensing at home delivery.

Note: This override provides for a dose up to 350 mg per day.

Venlafaxine HCl 75 mg immediate-release tablets

1. If the patient is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets be used AND would otherwise require two or more strengths be used), approve the requested quantity, not to exceed 150 tablets per dispensing at retail or 450 tablets per dispensing at home delivery.

Note: This override provides for a dose up to 375 mg per day.

2. If the patient has been started and stabilized on a dose greater than 300 mg per day or if the patient has been receiving 300 mg per day and the dose is now being increased, approve the requested quantity, not to exceed 150 tablets per dispensing at retail or 450 tablets per dispensing at home delivery.

Note: This override provides for a dose up to 375 mg per day.

Venlafaxine HCl 100 mg immediate-release tablets

No overrides recommended.

Venlafaxine HCl 37.5 mg extended-release capsules (Effexor XR, generic)

1. If the patient is taking 37.5 mg twice daily, approve 60 capsules per dispensing at retail and 180 capsules per dispensing at home delivery.
2. If the patient is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets be used AND would otherwise require two or more strengths be used), approve the requested quantity, not to exceed 300 capsules per dispensing at retail or 900 capsules per dispensing at home delivery.

Note: This override provides for a dose up to 375 mg per day.

Venlafaxine HCl 75 mg extended-release capsules (Effexor XR, generic)

1. If the patient is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets

be used AND would otherwise require two or more strengths be used), approve the requested quantity, not to exceed 150 capsules per dispensing at retail or 450 capsules per dispensing at home delivery.

Note: This override provides for a dose up to 375 mg per day.

2. If the patient has been started and stabilized on a dose greater than 225 mg per day or if the patient has been receiving 225 mg daily and the dose is now being increased, approve the requested quantity, not to exceed 150 capsules per dispensing at retail or 450 capsules per dispensing at home delivery.

Note: This override provides for a dose up to 375 mg per day.

Venlafaxine HCl 150 mg extended-release capsules (Effexor XR, generic)

1. If the patient has been started and stabilized on a dose greater than 225 mg per day or if the patient has been receiving 225 mg per day and the dose is now being increased, approve the requested quantity, not to exceed 60 capsules per dispensing at retail or 180 capsules per dispensing at home delivery.

Note: This override provides for a dose up to 300 mg per day.

Venlafaxine HCl 37.5 mg extended-release tablets (generic)

1. If the patient is taking 37.5 mg twice daily, approve 60 capsules per dispensing at retail and 180 tablets per dispensing at home delivery.
2. If the patient is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets be used AND would otherwise require two or more strengths be used), approve the requested quantity, not to exceed 300 tablets per dispensing at retail or 900 tablets per dispensing at home delivery.

Note: This override provides for a dose up to 375 mg per day.

Venlafaxine HCl 75 mg extended-release tablets (generic)

1. If the patient is taking 75 mg twice daily, approve 60 capsules per dispensing at retail and 180 tablets per dispensing at home delivery.
2. If the patient is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets be used AND would otherwise require two or more strengths be used), approve the requested quantity, not to exceed 150 tablets per dispensing at retail or 450 tablets per dispensing at home delivery.

Note: This override provides for a dose up to 375 mg per day.

3. If the patient has been started and stabilized on a dose greater than 225 mg per day or if the patient has been receiving 225 mg per day and the dose is now being increased, approve the requested quantity, not to exceed 150 tablets per dispensing at retail or 450 tablets per dispensing at home delivery.

Note: This override provides for a dose up to 375 mg per day.

Venlafaxine HCl 150 mg extended-release tablets (generic)

1. If the patient is taking 300 mg per day (as a single or divided dose), approve 60 tablets per dispensing at retail and 180 tablets per dispensing at home delivery.

Venlafaxine HCl 225 mg extended-release tablets

No overrides recommended.

Venlafaxine besylate 112.5 mg extended-release tablets

1. If the patient is taking 225 mg per day (as a single or divided dose), approve 60 tablets per dispensing at retail and 180 tablets per dispensing at home delivery.

Fetzima 20 mg extended-release capsules

1. If the patient is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets be used AND would otherwise require two or more strengths be used), approve the requested quantity, not to exceed 150 capsules per dispensing at retail or 450 capsules per dispensing at home delivery.

Note: This override provides for a dose up to 100 mg per day.

Fetzima 40 mg extended-release capsules

1. If the patient requires a dose of 40 mg twice daily, approve 60 capsules per dispensing at retail and 180 capsules per dispensing at home delivery.
2. If the patient requires a dose of 40 mg three times daily, approve 90 capsules per dispensing at retail and 270 capsules per dispensing at home delivery.

Fetzima 80 mg and 120 mg extended-release capsules and Fetzima Titration Pack
No overrides recommended.

Savella 12.5 mg tablets

1. If the patient is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets be used AND would otherwise require two or more strengths be used), approve the requested quantity, not to exceed 480 tablets per dispensing at retail or 1,440 tablets per dispensing at home delivery.

Note: This override provides for a dose up to 200 mg per day.

Savella 25 mg tablets

1. If the patient is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets be used AND would otherwise require two or more strengths be used), approve the requested quantity, not to exceed 240 tablets per dispensing at retail or 720 tablets per dispensing at home delivery.

Note: This override provides for a dose up to 200 mg per day.

Savella 50 mg tablets

1. If the patient is taking a dose that does not correspond to a commercially-available dosage form (that is, the dose requires multiple same strength tablets be used AND would otherwise require two or more strengths be used), approve the requested quantity, not to exceed 120 tablets per dispensing at retail or 360 tablets per dispensing at home delivery.

Note: This override provides for a dose up to 200 mg per day.

Savella 100 mg tablets and Titration Pack

No overrides recommended.

REFERENCES

1. Cymbalta® capsules [prescribing information]. Indianapolis, IN: Lilly; August 2023.
2. Desvenlafaxine extended-release tablets [prescribing information]. Cranbury, NJ: Sun; August 2023.
3. Drizalma Sprinkle™ delayed-release capsules [prescribing information]. Cranbury, NJ: Sun; August 2023.
4. Duloxetine delayed-release capsules [prescribing information]. Baltimore, MD: Lupin; December 2023.
5. Effexor XR® extended-release capsules [prescribing information]. Morgantown, WV: Viatrix; August 2023.
6. Fetzima® extended-release capsules [prescribing information]. North Chicago, IL: Abbvie; April 2024.
7. Pristiq® extended-release tablets [prescribing information]. Philadelphia, PA: Wyeth/Pfizer; August 2023.
8. Savella® tablets [prescribing information]. North Chicago, IL: AbbVie; May 2024.
9. Venlafaxine hydrochloride tablets [prescribing information]. Parsippany, NJ: Teva; August 2023.
10. Venlafaxine hydrochloride extended-release tablets [prescribing information]. Cranbury, NJ: Sun; September 2023.
11. Venlafaxine besylate extended-release tablets [prescribing information]. Morristown, NJ: Almatica; August 2023.

HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria changes. Khedezla (desvenlafaxine 50 mg and 100 mg extended-release tablets) were removed from the policy (obsolete for more than 3 years). Throughout policy, override quantities were updated to reflect maximum capsule/tablet numbers. Previously, override quantities per listed as a maximum dose per day.	06/08/2023
Annual Revision	No criteria changes.	07/01/2024

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2024 The Cigna Group.